Adial Pharmaceuticals Inc
ADIL3.120USD
-0.305-8.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
74.37MMarket Cap
LossP/E TTM
More Details of Adial Pharmaceuticals Inc Company
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Adial Pharmaceuticals Inc Info
Ticker SymbolADIL
Company nameAdial Pharmaceuticals Inc
IPO dateJul 27, 2018
CEOClaiborne (Cary J)
Number of employees5
Security typeOrdinary Share
Fiscal year-endJul 27
Address1180 Seminole Trail
CityCHARLOTTESVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code22901
Phone14344229800
Websitehttps://www.adialpharma.com/
Ticker SymbolADIL
IPO dateJul 27, 2018
CEOClaiborne (Cary J)
Company Executives of Adial Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
100.80K
+40000.00%
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
100.80K
+40000.00%
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
1.61%
Armistice Capital LLC
1.21%
Geode Capital Management, L.L.C.
0.59%
The Vanguard Group, Inc.
0.56%
Citadel Advisors LLC
0.52%
Other
95.51%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
1.61%
Armistice Capital LLC
1.21%
Geode Capital Management, L.L.C.
0.59%
The Vanguard Group, Inc.
0.56%
Citadel Advisors LLC
0.52%
Other
95.51%
Shareholder Types
Shareholders
Proportion
Hedge Fund
1.78%
Corporation
1.63%
Investment Advisor
0.94%
Investment Advisor/Hedge Fund
0.59%
Individual Investor
0.45%
Research Firm
0.05%
Other
94.55%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
944.43K
1.50%
--
2025Q3
33
944.43K
1.65%
+373.38K
2025Q2
38
571.05K
2.50%
-3.54K
2025Q1
39
574.59K
5.92%
+185.57K
2024Q4
40
638.99K
4.37%
+99.22K
2024Q3
41
539.76K
5.40%
+246.68K
2024Q2
45
293.30K
9.08%
+102.21K
2024Q1
45
191.09K
7.23%
-101.96K
2023Q4
47
264.60K
8.46%
+207.34K
2023Q3
47
57.35K
15.43%
-34.64K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
446.28K
1.61%
+446.28K
--
Jun 20, 2025
Armistice Capital LLC
336.31K
1.21%
+336.31K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
164.13K
0.59%
+95.28K
+138.38%
Sep 30, 2025
The Vanguard Group, Inc.
156.02K
0.56%
+142.87K
+1085.68%
Sep 30, 2025
Citadel Advisors LLC
143.79K
0.52%
+143.79K
--
Sep 30, 2025
Claiborne (Cary J)
100.80K
0.36%
+40.00K
+65.79%
Dec 30, 2025
Manchester Capital Management LLC
48.10K
0.17%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
27.77K
0.1%
--
--
Sep 30, 2025
Newman (James W. Jr.)
13.54K
0.05%
--
--
Dec 30, 2025
Two Sigma Investments, LP
12.84K
0.05%
+2.04K
+18.88%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Feb 03, 2026
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Date
Ex-dividend Date
Type
Ratio
Feb 03, 2026
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
